Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
19 January 2018
Melanoma Institute Australia is delighted to be the charity partner for the Toyota Country Music Festival 2018 in Tamworth, with the traditional festival hat giveaway to raise vital funds for research into melanoma prevention and treatment.
Melanoma is the most deadly form of skin cancer. Australia has one of the highest rates in the world with one person dying from the disease every five hours. It is the most common cancer affecting 15 to 39 year olds and incidence in the over 60s age bracket is also increasing. 14,000 Australians are expected to be diagnosed with melanoma this year.
Melanoma Institute Australia is leading the world charge to prevent melanoma and find a cure, and funds raised at this year’s Toyota Country Music Festival through their annual hat fundraiser will help fuel ongoing research.
Toyota ambassadors, including Lee himself and The McClymonts, will be making surprise appearances to support this cause as well during the Festival to meet fans and show their support in raising awareness of sun safety.
Prevention is the key to saving lives from melanoma. All Australians are urged to wear SPF 50+ sunscreen and re-apply at least every two hours or after swimming or activity; cover up with a broad-brimmed hat, long pants and shirt and sunglasses; and seek shade in the heat of the day.
Hats will be available daily at the Toyota Fanzone at 10am, 12pm, 2pm and 4pm in exchange for a two-dollar donation with all proceeds going to Melanoma Institute Australia
Join us at the 2nd Melanoma Patients Australia webinar 'Psychological Health & Wellbeing'.
You're invited to be a C2S charity superstar, and together we can run over melanoma!
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.